APLS-12.49%20.0%
ARQT+88.47%20.0%
CYTK+135.23%20.0%
HALO+36.42%20.0%
SPRY-56.17%20.0%
As of Jul 10, 2026, 7:14 AM ET
Biotech '25: Commercial / Late Stage Constituents
| Company | Wgt | Premarket % | 1D % | 10D % | MTD % | YTD % | IranWar % | LibDay % | 1Yr % | Mkt Cap |
|---|---|---|---|---|---|---|---|---|---|---|
Cytokinetics, IncorporatedCYTK | 20.0% | 1.02% | 1.40% | -1.36% | 0.95% | 35.46% | 38.33% | 113.84% | 135.23% | $10.71B |
Halozyme Therapeutics, Inc.HALO | 20.0% | -0.14% | -2.18% | 1.87% | 2.09% | 16.82% | 13.07% | 24.75% | 36.42% | $9.33B |
Arcutis Biotherapeutics, Inc.ARQT | 20.0% | 1.58% | 0.98% | 7.55% | 11.38% | -0.90% | 6.71% | 73.37% | 88.47% | $3.60B |
Apellis Pharmaceuticals, Inc.APLS | 20.0% | 0.00% | 0.00% | 0.00% | 0.00% | -31.97% | -18.46% | -25.70% | -12.49% | $2.19B |
ARS Pharmaceuticals, Inc.SPRY | 20.0% | 0.57% | -2.72% | -7.94% | -0.76% | -32.36% | -15.09% | -39.62% | -56.17% | $782.5M |
| Theme return | — | 0.61% | -0.50% | 0.02% | 3.38% | -1.62% | 6.33% | 33.01% | 32.29% | — |
| Average | 20.0% | 0.61% | -0.50% | 0.02% | 2.73% | -2.59% | 4.91% | 29.33% | 38.29% | $5.32B |
| Median | 20.0% | 0.57% | 0.00% | 0.00% | 0.95% | -0.90% | 6.71% | 24.75% | 36.42% | $3.60B |
| Std Dev | 0.0% | 0.64% | 1.66% | 5.01% | 4.43% | 26.75% | 20.65% | 58.11% | 68.44% | $3.96B |
| Min | 20.0% | -0.14% | -2.72% | -7.94% | -0.76% | -32.36% | -18.46% | -39.62% | -56.17% | $782.5M |
| Max | 20.0% | 1.58% | 1.40% | 7.55% | 11.38% | 35.46% | 38.33% | 113.84% | 135.23% | $10.71B |
| % Positive Tickers | 60.00% | 40.00% | 40.00% | 60.00% | 40.00% | 60.00% | 60.00% | 60.00% |
About this theme
Biotech '25: Commercial / Late Stage tracks 5 publicly listed stocks in this theme: APLS, ARQT, CYTK, HALO, SPRY. See the constituent table for details.